PriCara, a division of Ortho-McNeil-Janssen Pharmaceuticals, has announced the launch of Nucynta (tapentadol) CII immediate release tablets. Nucynta works by binding with mu-opioid receptors and inhibiting norepinephrine re-uptake.
This new medication, for the relief of moderate-to-severe acute pain in patients 18 years of age or older, is now available by prescription only in 50mg, 75mg and 100mg tablets, said the company.
On November 20, 2008, FDA approved Nucynta for the pain relief in cases of acute pain. The US Drug Enforcement Agency has placed Nucynta into schedule II of the Controlled Substances Act.
PriCara is going to market Nucynta in the US.